Agilent - Breakthroughs in Immunotherapy- 2019 - 5

Interview

Breakthroughs in Immunotherapy
A Chat with Renowned American
Immunologist and Oncologist, Dr. Carl June

gilent has steadily been developing innovative cell-based
solutions designed to enable researchers and developers to
overcome the challenges and capture the opportunities faced
in the rapidly growing field of immunotherapy. Recently David Ferrick,
an executive in the Cell Analysis Division at Agilent, caught up with
Carl June, a professor at the University of Pennsylvania and Abramson
Cancer Center, to discuss their perspectives on these unique challenges
and opportunities. Dr. June has not served as a consultant for Agilent
and has not received payments from Agilent.
David Ferrick: Carl, as you know, our relationship with you over the past
few years has really helped us to advance several innovative solutions
comprised of purpose-built tools in immunotherapy. Your guidance on
the needs of this rapidly evolving field are invaluable. I'd like to focus on
Dr. Carl June
three areas: the engineering of human cells, how cell analysis tools are
enabling cell therapy to reach its potential, and next steps in cell manufacturing QA/QC for cell-based therapies. As a pioneer in the engineering of human cells, how do you see
the field evolving, and what do you think are the greatest challenges today?
Carl June: We're at an early stage where the proof of concept has been shown, and now accepted,
that you can make synthetically engineered T cells that have enhanced performance characteristics in
5

| GENengnews.com

Additional Info

View the webinar:
"The bioenergetics
of immune cell
persistence
in the tumor
microenvironment"

https://seahorseinfo.agilent.com/acton/fs/blocks/showLandingPage/a/10967/p/p-01e2/t/page/fm/2 http://www.GENengnews.com

Agilent - Breakthroughs in Immunotherapy- 2019

Table of Contents for the Digital Edition of Agilent - Breakthroughs in Immunotherapy- 2019